Research on the Role of SLC1A5 in the Development of Esophageal Cancer

NCT ID: NCT02633436

Last Updated: 2016-08-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-12-31

Study Completion Date

2018-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To explore the significance of Solute Carrier Family 1 Member 5 (SLC1A5) in the occurrence of esophageal cancer, by comparing the expression of SLC1A5 between esophageal cancer tissues and adjacent tissues.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will be an observational study. The investigators will aim to enroll 100 male and female adult patients (aged 18 years and over) of all ethnicities/races, who have been referred to the Fourth Affiliated Hospital of Guangxi Medical University for esophageal cancer.

The investigators will be using a standardized data collection form. This is an observational study in which standard of care will be practiced and the patients are not placed at additional risk from participating in this study. However, as the investigators are collecting data prospectively, all participants will sign consent. An attempt will be made to see if there is a correlation between the expression of SLC1A5 with esophageal cancer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Cancer Amino Acid Transport Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cancer tissues

SLC1A5 expression of esophageal cancer tissues from patients

SLC1A5 expression

Intervention Type OTHER

To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.

paired adjacent tissues

SLC1A5 expression of paired adjacent esophageal tissues from patients

SLC1A5 expression

Intervention Type OTHER

To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SLC1A5 expression

To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with histologically proven esophageal cancer;
2. Age ≥18 years;
3. All patients must sign consent forms voluntarily;

Exclusion Criteria

1. Inability to obtain histologic proof of malignancy.
2. Age \<18 years;
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Liuzhou Maternity and Child Healthcare Hospital

OTHER

Sponsor Role collaborator

Fourth Affiliated Hospital of Guangxi Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xiangcheng Wei

Role: PRINCIPAL_INVESTIGATOR

Guangxi Medical University Institutional Review Board

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Liuzhou Maternity and Child Healthcare Hospital

Liuzhou, Guangxi, China

Site Status RECRUITING

The Fourth Affiliated Hospital of Guangxi Medical University

Liuzhou, Guangxi, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Shengming Dai, Dr.

Role: CONTACT

+86 13978026884

Zheng Peng

Role: CONTACT

+86 18589966550

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xiaolan Lv

Role: primary

+86 15577727711

Zheng Peng

Role: primary

+86 18589966550

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PJK201518

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.